A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant plural mesothelioma

Keyphrases

• Biomarker Profile 100%
• Mesothelioma 100%
• Cisplatin 100%
• Vinorelbine 100%
• ERCC1 100%
• βIII-tubulin 83%
• Malignant Pleural Mesothelioma 66%
• Progression-free Survival 50%
• Overall Survival 50%
• Breast Cancer Susceptibility Gene 1 (BRCA1) 50%
• Immunostaining 33%
• Treatment-resistant 33%
• Immunohistochemistry 33%
• Tumor Specimens 16%
• Treatment-resistant Patients 16%
• Dismal Prognosis 16%
• Tumor Tissue 16%
• Formalin-fixed Paraffin-embedded Tissue 16%
• Treatment Response 16%
• Patients Included 16%
• Multivariate Analysis 16%
• Predictive Biomarker 16%
• Response Profiles 16%
• Treatment Results 16%
• Upper Quartile 16%
• Direct Therapy 16%
• Phase II Trial 16%
• Predictive Power 16%
• Median Progression-free Survival 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Mesothelioma 100%
• Tubulin 100%
• Cisplatin 100%
• Biological Marker 100%
• Progression Free Survival 80%
• Pleura Mesothelioma 80%
• Overall Survival 60%
• Neoplasm 40%
• Formaldehyde 20%
• Phase II Trials 20%